Tirzepatide vs Semaglutide
Tirzepatide vs Semaglutide is the most-searched research peptide comparison of 2026. The essential difference: Semaglutide is a single GLP-1 receptor agonist. Tirzepatide adds a second receptor — GIP — making it a dual agonist.
Below is a side-by-side comparison covering receptor profile, vial strengths and research context.
Side-by-side
| Tirzepatide | Semaglutide | |
|---|---|---|
| Receptor profile | Dual: GLP-1 / GIP | Single: GLP-1 |
| Class | Dual agonist | Mono agonist (GLP-1 analogue) |
| Vial strengths | 20mg · 40mg | 30mg |
| Dosing cadence | Weekly (long-acting) | Weekly (long-acting) |
| Research maturity | Fast-growing dual-agonist literature | Established reference peptide |
| Purity (HPLC) | 99%+ | 99%+ |
Mechanism
Semaglutide is a GLP-1 analogue — the benchmark for characterising GLP-1 receptor pharmacology (cAMP response, β-arrestin recruitment, receptor internalisation).
Tirzepatide adds GIP (glucose-dependent insulinotropic polypeptide) receptor activity from a single peptide backbone — the basis for its distinct metabolic profile in published research.
Reconstitution
Both peptides are supplied as lyophilised powder and reconstituted with bacteriostatic water. Use our free peptide calculator for exact volumes. Store at 2–8°C after reconstitution and use within 28 days.
Browse related products
View full shopFrequently asked questions
What's the difference between Tirzepatide and Semaglutide?
Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual agonist — it activates both GLP-1 and GIP receptors from one molecule. The added GIP receptor activity is the mechanistic difference.
Which has more research behind it?
Semaglutide has the longer track record as an established reference GLP-1 peptide. Tirzepatide has a rapidly growing body of published dual-agonist literature and is now one of the most-studied peptides in metabolic research.
What vial strengths are available?
Tirzepatide is stocked in 20mg and 40mg vials. Semaglutide is stocked in 30mg vials. All are HPLC verified at 99%+ purity with batch-specific COAs.
Are the half-lives similar?
Both are long-acting research peptides designed for weekly protocols. Reported half-lives are broadly similar, though exact values differ between published sources and formulations.
Which is better for research?
Neither is universally 'better' — it depends on the receptor profile your protocol needs. Semaglutide for pure GLP-1 studies; Tirzepatide when dual GLP-1 / GIP activity is required.
Disclaimer: All products sold by Peptides UK 4U are for laboratory and research purposes only. They are not intended for human or animal consumption, diagnosis, treatment or prevention of any disease.